CD86 and autoimmune thrombocytopenic purpura: Our data demonstrated that the treatment of low‐dose DAC decreased M1 macrophages (F4/80+ CD86+) and increased M2 macrophages (F4/80+ CD206+) in spleen when compared with ITP mice (Figure 4B), and so were results observed in FCM (Figure 4C,D, Figure s7A).